Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers

John K. Chan, Deanna Teoh, Jessica M. Hu, +3

Gynecologic Oncology

Tumoral PathologyMedicineGynecologyPathologyCancer Prognosis +5

A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

Angeles Alvarez Secord, Deanna Teoh, William T. Barry, +7

Clinical Cancer Research

Factors Influencing Same-day Hospital Discharge and Risk Factors for Readmission After Robotic Surgery in the Gynecologic Oncology Patient Population

Colleen Rivard, Kelly Casserly, Mary Ann Anderson, +2

Journal of Minimally Invasive Gynecology

Gynecologic SurgerySurgical OncologyGynecological SurgeryPatient SafetyRobotic Surgery +10

Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study

John K. Chan, Chunqiao Tian, Deanna Teoh, +4

Gynecologic Oncology

Gynecological SurgeryMedicineCancer RecurrenceCancer ManagementGynecology +4

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines

Brittany A. Davidson, Jennifer M. Rubatt, David L. Corcoran, +10

Frontiers in Oncology

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Deanna Teoh, Tina A. Ayeni, Jennifer M. Rubatt, +7

Gynecologic Oncology

Synergistic ActivityOncologyMedicineCancer BiologyAnti-cancer Agent +5

Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Antonio Jimeno, Shilpa Gupta, Ryan J. Sullivan, +16

Cancer Research

ImmunologyImmunoeditingPathologyImmunotherapyPd-l1 Levels +18

Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer

Emil Lou, Rachel I. Vogel, Spencer Hoostal, +4

JAMA Oncology

Endocrine-related CancerMedicineMetronomic TherapyTumor-stroma ProportionPathology +9

Siglec-6 is expressed in gestational trophoblastic disease and affects proliferation, apoptosis and invasion

Kristen K. Rumer, Rhea S Larivee, Martina Zink, +5

Endocrine Related Cancer

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations

Robin A. Lacour, Shannon N. Westin, Larissa A. Meyer, +18

Gynecologic Oncology

Somatic VariantMedicineBrca2 Gene MutationsGynecologyPathology +4